# The First in Human Study of QLS2319 in Healthy Subjects and Cancer Cachexia

> **NCT07735104** · PHASE1,PHASE2 · RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 88 (estimated)

## Conditions studied

- Cancer Cachexia
- Cancer Cachexia Syndrome

## Interventions

- **DRUG:** QLS2319
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07735104
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-16
- **Primary completion:** 2028-10-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2026-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07735104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07735104, "The First in Human Study of QLS2319 in Healthy Subjects and Cancer Cachexia". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07735104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*